Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported selling 15,000 shares of common stock in two direct transactions on October 1, 2026: 12,000 shares at a reported $147.7190 per share and 3,000 shares at $148.6265 per share. The applicable sale-price ranges were $147.21 to $148.205 and $148.23 to $149.13, respectively.
At Gilead Sciences, Inc., SVP, Controllership Erin Burkhart converted 2,223 restricted stock units into 2,223 common shares on September 22, 2026. Another 768 shares were delivered or withheld for payment of exercise price or tax liability at $152.67 per share. Her reported post-transaction position included 9,022 restricted stock units. No Rule 10b5-1 plan is reported.
Gilead Sciences, Inc. (GILD) reported that Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock on September 15, 2026 at $145.29 per share in an open-market transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, and left him holding 164,096 shares directly.
GILEAD SCIENCES, INC. (GILD) reports that Chief Commercial and Corporate Affairs Officer Johanna Mercier sold a total of 3,000 shares of common stock on September 15, 2026 in three open-market or private transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025, with sale prices ranging from $143.16 to $144.775 per share for portions of the shares. The filing does not state her remaining holdings.
GILEAD SCIENCES, INC. (GILD) has a notice under Rule 144 for a planned sale of common stock by Johanna Mercier. The notice covers 3,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $432,646.20 as of the filing. The shares to be sold were acquired as Performance Shares from the issuer on February 4, 2025, and are listed on NASDAQ.
In addition, Johanna Mercier reported prior sales of Gilead common stock during the past three months, including 28,000 shares on August 17, 2026 for $3,853,907.85 and 3,000 shares on July 15, 2026 for $389,757.60.
GILEAD SCIENCES, INC. (GILD) received a Rule 144 notice from officer Andrew Dickinson covering a proposed sale of 3,000 shares of common stock. The shares, held in an account at Morgan Stanley Smith Barney LLC Executive Financial Services, have an indicated aggregate market value of $435,870.00 and are listed on NASDAQ.
The shares to be sold were acquired as Performance Shares from the issuer on January 31, 2024. Dickinson also reports prior Rule 144 sales of 3,000 shares on July 15, 2026 for $389,776.80 and 3,000 shares on August 17, 2026 for $415,080.00 within the preceding three months.
GILEAD SCIENCES, INC. (GILD) reported that Chief Financial Officer Andrew D. Dickinson exercised restricted stock units for 2,797 shares of common stock on September 10, 2026. The same number of RSUs was converted and removed, and 1,347 shares of common stock were delivered or withheld to cover the exercise price or tax liability, leaving 25,054 restricted stock units directly held. No Rule 10b5-1 trading plan is reported.
Gilead Sciences, Inc. (GILD) reported that Chief Medical Officer Dietmar Berger had restricted stock units vest into 533 shares of common stock on September 10, 2026. Of these, 263 shares were delivered or withheld to cover the exercise price or tax liability, leaving 270 net shares acquired as common stock. The RSU award follows a four-year vesting schedule, and no Rule 10b5-1 trading plan is reported for these transactions.
GILEAD SCIENCES, INC. (GILD) reported that Chief Comm & Corp Aff Officer Johanna Mercier exercised 2,797 restricted stock units into an equal number of shares of common stock on September 10, 2026. Of these, 1,347 shares of common stock were delivered or withheld to pay the exercise price or tax liability, leaving 25,054 restricted stock units reported as remaining. Each restricted stock unit represents the right to receive one share of common stock and follows a 4-year vesting schedule with 25% vesting after one year and 6.25% vesting quarterly thereafter.
GILEAD SCIENCES, INC. (GILD) reported that executive vice president and general counsel Keeley M. Cain Wettan had 590 restricted stock units convert into 590 shares of common stock on September 10, 2026. Of these shares, 285 were delivered or withheld at $144.81 per share to cover the exercise price or tax liability, and Cain Wettan continues to hold 13,405 restricted stock units directly. The units represent the right to receive common shares and follow a four-year vesting schedule with 25% vesting after one year and 6.25% vesting quarterly thereafter, and no Rule 10b5-1 trading plan is reported for these transactions.